Comments on the WHO Global Tuberculosis Report 2024:Progress,Challenges and Innovations for Achieving End TB Strategy by 2035  

作　　者：Kefan Bi Yanlin Zhao Shuihua Lu Kaijin Xu Ying Zhang 

机构地区：[1]State Key Laboratory for Diagnosis and Treatment of Infectious Diseases,National Clinical Research Center for Infectious Diseases,National Medical Center for Infectious Diseases,Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases,The First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou,China [2]National Center for Tuberculosis Control and Prevention,Chinese Center for Disease Control and Prevention,Beijing,China [3]National Clinical Research Center for Infectious Disease,Shenzhen Third People’s Hospital,Shenzhen,China [4]Jinan Microecological Biomedicine Shandong Laboratory,Jinan,China.

出　　处：《Infectious Microbes & Diseases》2025年第1期1-4,共4页感染微生物与疾病(英文)

基　　金：supported by the National Infectious Disease Medical Center(B2022011-1);Jinan Microecological Biomedicine Shandong Laboratory project(JNL-2022050B)。

摘　　要：The 2024World Health Organization(WHO)Global Tuberculosis Report underscores progress and persisting challenges in the fight against tuberculosis(TB).1 TB remains a significant global health concern,with a slight stabilization in the incidence rate following disruptions caused by the COVID-19 pandemic.However,achieving the goals of the End TB Strategy by 2035 requires more accelerated efforts.2 The report reveals that,while the global rise in TB incidence has slowed,the number of people falling ill with TB continues to rise,highlighted by a global estimate of 10.8 million TB cases in 2023,with 30 high TB burden countries accounting for 87%of the global total TB cases.It is noteworthy that five countries accounted for 56%of the global TB burden,with India contributing the largest share at 26%,followed by Indonesia at 10%,China at 6.8%,the Philippines at 6.8%and Pakistan at 6.3%.Despite a reduction in TB deaths globally(approximately 1.25 million in 2023 compared with 1.32 million in 2022),TB has reclaimed its position as the leading cause of death from a single infectious agent,surpassing COVID-19.TB deaths are primarily due to complications resulting from untreated or poorly managed TB infections.The leading causes of death include the progression of pulmonary TB and TB with HIV/AIDS.Highmortality TB diseases such as tuberculous meningitis,miliary TB and disseminated TB remain critically neglected,receiving insufficient attention and lacking adequate treatment strategies.3–6 Addressing this neglect requires urgent investment in advanced diagnostics,personalized treatments and innovative drug therapies.Expanding healthcare capacity and establishing effective treatment standards are vital to combating these overlooked diseases and reducing mortality,particularly amid rising drug resistance.

关 键 词：Global Tuberculosis Report WHO tuberculosis burden 

分 类 号：R52[医药卫生—内科学]